J B Vermorken

Summary

Affiliation: University Hospital Antwerp
Country: Belgium

Publications

  1. ncbi request reprint Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies
    Jan B Vermorken
    Department of Medical Oncology, University Hospital Antwerp, Edegem, Belgium
    Cancer 112:2710-9. 2008
  2. doi request reprint Second-line randomized trials in epithelial ovarian cancer
    J B Vermorken
    Department of Medical Oncology, University Hospital Antwerp, Edegem, Belgium
    Int J Gynecol Cancer 18:59-66. 2008
  3. pmc A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours
    M Rasschaert
    Department of Medical Oncology, University Hospital Antwerp, Wilrijkstraat 10, 2650 Edegem, Belgium
    Br J Cancer 96:1692-8. 2007
  4. pmc Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck
    R Mesia
    Department of Medical Oncology, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain
    Ann Oncol 21:1967-73. 2010
  5. pmc Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study
    L Licitra
    Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy
    Ann Oncol 22:1078-87. 2011
  6. pmc Biologic therapy in head and neck cancer: a road with hurdles
    Pol Specenier
    Department of Medical Oncology, Antwerp University Hospital, Wilrijkstraat 10, 2650 Edegem, Belgium
    ISRN Oncol 2012:163752. 2012
  7. pmc RapidArc, SmartArc and TomoHD compared with classical step and shoot and sliding window intensity modulated radiotherapy in an oropharyngeal cancer treatment plan comparison
    Dirk Van Gestel
    Department of Radiotherapy, University Radiotherapy department Antwerp UZA ZNA, Lindendreef 1, 2020 Antwerp, Belgium
    Radiat Oncol 8:37. 2013
  8. doi request reprint Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck
    J B Vermorken
    Antwerp University Hospital, Edegem, Belgium
    Eur J Cancer 49:2877-83. 2013
  9. ncbi request reprint Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
    Jan B Vermorken
    Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium
    Lancet Oncol 14:697-710. 2013
  10. pmc The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines
    Bea Pauwels
    Laboratory of Cancer Research and Clinical Oncology, Department of Medical Oncology, University of Antwerp UA UZA, Wilrijk, Belgium
    BMC Cancer 6:142. 2006

Detail Information

Publications92

  1. ncbi request reprint Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies
    Jan B Vermorken
    Department of Medical Oncology, University Hospital Antwerp, Edegem, Belgium
    Cancer 112:2710-9. 2008
    ..The activity of cetuximab was compared with that of commonly used treatments in this setting...
  2. doi request reprint Second-line randomized trials in epithelial ovarian cancer
    J B Vermorken
    Department of Medical Oncology, University Hospital Antwerp, Edegem, Belgium
    Int J Gynecol Cancer 18:59-66. 2008
    ..However, in all circumstances other aspects such as toxicity (and earlier experienced toxicity), clinical condition, convenience of administration, costs, and patient preference should be considered in the final selection of treatment...
  3. pmc A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours
    M Rasschaert
    Department of Medical Oncology, University Hospital Antwerp, Wilrijkstraat 10, 2650 Edegem, Belgium
    Br J Cancer 96:1692-8. 2007
    ..3% (range 2.7-26%). The MTD of BM in the present dose schedule was 180 mg m(-2) on day 1+2. Thrombocytopaenia was dose limiting. The recommended dose for future phase II trials with this schedule is 160 mg m(-2) per day...
  4. pmc Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck
    R Mesia
    Department of Medical Oncology, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain
    Ann Oncol 21:1967-73. 2010
    ..This analysis of the trial assessed the impact of treatment on quality of life (QoL)...
  5. pmc Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study
    L Licitra
    Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy
    Ann Oncol 22:1078-87. 2011
    ..The aim of this investigation was to evaluate elevated tumor EGFR gene copy number as a predictive biomarker in EXTREME study patients...
  6. pmc Biologic therapy in head and neck cancer: a road with hurdles
    Pol Specenier
    Department of Medical Oncology, Antwerp University Hospital, Wilrijkstraat 10, 2650 Edegem, Belgium
    ISRN Oncol 2012:163752. 2012
    ....
  7. pmc RapidArc, SmartArc and TomoHD compared with classical step and shoot and sliding window intensity modulated radiotherapy in an oropharyngeal cancer treatment plan comparison
    Dirk Van Gestel
    Department of Radiotherapy, University Radiotherapy department Antwerp UZA ZNA, Lindendreef 1, 2020 Antwerp, Belgium
    Radiat Oncol 8:37. 2013
    ..The present paper aims to compare Step and Shoot (SS) IMRT, Sliding Window (SW) IMRT, RapidArc (RA) planned with Eclipse, Elekta VMAT planned with SmartArc (SA) and helical TomoHD™ (HT)...
  8. doi request reprint Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck
    J B Vermorken
    Antwerp University Hospital, Edegem, Belgium
    Eur J Cancer 49:2877-83. 2013
    ..Pemetrexed has shown activity in SCCHN. This phase II study evaluated pemetrexed with cisplatin and cetuximab in recurrent/metastatic SCCHN...
  9. ncbi request reprint Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
    Jan B Vermorken
    Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium
    Lancet Oncol 14:697-710. 2013
    ..We assessed the efficacy and safety of panitumumab combined with cisplatin and fluorouracil as first-line treatment for these patients...
  10. pmc The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines
    Bea Pauwels
    Laboratory of Cancer Research and Clinical Oncology, Department of Medical Oncology, University of Antwerp UA UZA, Wilrijk, Belgium
    BMC Cancer 6:142. 2006
    ..In the present study, the relation between deoxycytidine kinase (dCK) activity and the radiosensitising effect of gemcitabine was investigated in eight different human tumour cell lines...
  11. pmc A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer
    Helmut Friess
    Department of General Surgery, University of Heidelberg, Heidelberg, Germany
    BMC Cancer 6:285. 2006
    ..In this study, the treatment effects of the angiogenesis inhibitor Cilengitide and gemcitabine were compared with gemcitabine alone in patients with advanced unresectable pancreatic cancer...
  12. doi request reprint Optimal treatment for recurrent/metastatic head and neck cancer
    J B Vermorken
    Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium
    Ann Oncol 21:vii252-61. 2010
    ....
  13. ncbi request reprint Clinical trials in ovarian carcinoma: study methodology
    J B Vermorken
    Department of Oncology, University Hospital Antwerp, Edegem, Belgium
    Ann Oncol 16:viii20-viii29. 2005
  14. pmc Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part
    J B Vermorken
    Department of Medical Oncology, Antwerp University Hospital, Wilrijkstraat 10, Edegem 2650, Belgium
    Br J Cancer 104:1691-6. 2011
    ..Novel therapies are needed to improve the poor prognosis of patients with recurrent and/or metastatic squamous cell cancer of the head and neck (SCCHN)...
  15. ncbi request reprint The Gynecologic Cancer Intergroup (GCIG): history and current status
    J B Vermorken
    Department of Medical Oncology, University Hospital Antwerp, Edegem, Belgium
    Ann Oncol 16:viii39-viii42. 2005
  16. doi request reprint How to select targeted therapy in renal cell cancer
    B Escudier
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 21:vii59-62. 2010
    ..In addition, in front of every patient, the physician will need to raise important questions such as whether the patient should be treated, should receive surgery and also what is his prognosis. The different options are described here...
  17. ncbi request reprint Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based the
    Jan B Vermorken
    Department of Medical Oncology, University Hospital Antwerpen, Edegem, Belgium
    J Clin Oncol 25:2171-7. 2007
    ....
  18. ncbi request reprint Platinum-based chemotherapy plus cetuximab in head and neck cancer
    Jan B Vermorken
    Antwerp University Hospital, Department of Medical Oncology, Edegem, Belgium
    N Engl J Med 359:1116-27. 2008
    ..We investigated the efficacy of cetuximab plus platinum-based chemotherapy as first-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck...
  19. ncbi request reprint Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer
    Jan B Vermorken
    Department of Medical Oncology, Universitair Ziekenhuis Antwerpen, Edegem, Belgium
    N Engl J Med 357:1695-704. 2007
    ..We compared TPF with PF as induction chemotherapy in patients with locoregionally advanced, unresectable disease...
  20. ncbi request reprint Phase II feasibility study of concurrent radiotherapy and gemcitabine in chemonaive patients with squamous cell carcinoma of the head and neck: long-term follow up data
    P M Specenier
    Department of Medical Oncology, University Hospital Antwerp, Edegem, Belgium
    Ann Oncol 18:1856-60. 2007
    ..Gemcitabine (GEM) is a potent radiosensitizer and in addition has activity as an anticancer agent in SCCHN...
  21. ncbi request reprint Role of red blood cells in pharmacokinetics of chemotherapeutic agents
    D Schrijvers
    Department of Medical Oncology, University Hospital Antwerp, Edegem, Belgium
    Anticancer Drugs 10:147-53. 1999
    ..In this review, the role of the red blood cell in storage, transport and metabolism of different anti-cancer drugs is described...
  22. ncbi request reprint Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study
    D Schrijvers
    University Hospital Antwerp, Edegem, Belgium
    Ann Oncol 15:638-45. 2004
    ..To determine the safety profile and activity of the combination of docetaxel, cisplatin and 5-fluorouracil (5-FU) in chemotherapy-naive patients with squamous cell carcinoma of the head and neck (SCCHN)...
  23. pmc In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects
    C Simoens
    Laboratory of Cancer Research and Clinical Oncology, Department of Medical Oncology, University of Antwerp UIA UZA, Universiteitsplein 1, B 2610 Wilrijk, Antwerp, Belgium
    Br J Cancer 89:2305-11. 2003
    ..In conclusion, ET-743 has moderate cell line-dependent radiosensitising properties; however, only when cytotoxic concentrations of ET-743 are used. In one of the four cell lines tested, no radiosensitisation was observed...
  24. ncbi request reprint The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer
    J B Vermorken
    Department of Medical Oncology, University Hospital Antwerp, Edegem, Belgium
    Int J Gynecol Cancer 11:21-30. 2001
    ..Although activity has been shown, no data from randomized comparative trials are available to allow a judgement on its potential advantages...
  25. ncbi request reprint Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers
    C Theodore
    Institut Gustave Roussy, Department of Medicine, 39, rue Camille Desmoulins 94805, Villejuif, France
    Eur J Cancer 41:1150-7. 2005
    ..SCH66336 had no effect on the pharmacokinetics of gemcitabine. Randomised trials should be undertaken to clarify the role of SCH66336 in combination with gemcitabine in cancer treatment...
  26. doi request reprint A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors
    J B Vermorken
    Department of Medical Oncology, Antwerp University Hospital, Edegem
    Ann Oncol 24:1392-400. 2013
    ....
  27. ncbi request reprint Cytomegalovirus colitis after administration of docetaxel-5-fluorouracil-cisplatin chemotherapy for locally advanced hypopharyngeal cancer
    J Van den Brande
    Department of Medical Oncology, University Hospital Antwerp UZA, Edegem, Belgium
    Ann Oncol 10:1369-72. 1999
    ..CMV infection should therefore be included in the differential diagnosis of GI disease in all patients, and when suspected, the clinician should pursue appropriate diagnostic and therapeutic interventions...
  28. ncbi request reprint Long-term results of surgical resection of lung metastases
    J M Hendriks
    Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Edegem, Belgium
    Acta Chir Belg 101:267-72. 2001
    ..It is in accordance with some reports that a short disease-free interval, numerous lung metastases, or recurrence after the first metastasectomy should not preclude patients from operation...
  29. ncbi request reprint A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer
    J Tabernero
    Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Ann Oncol 15:1358-65. 2004
    ..A phase II randomised trial was conducted to evaluate the tolerability and activity of weekly or 3-weekly docetaxel in patients with metastatic breast cancer...
  30. pmc KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis
    V Deschoolmeester
    Laboratory of Cancer Research and Clinical Oncology, Department of Medical Oncology, University of Antwerp Antwerp University Hospital, Wilrijk 2610, Belgium
    Br J Cancer 103:1627-36. 2010
    ..Direct sequencing was used to confirm and characterise HRMA results...
  31. ncbi request reprint Pharmacologic study of paclitaxel administered with or without the cytoprotective agent amifostine, and given as a single agent or in combination with epirubicin and cisplatin in patients with advanced solid tumors
    J Van den Brande
    Department of Medical Oncology, University Hospital Antwerpen, Edegem, Belgium
    Am J Clin Oncol 24:401-3. 2001
    ..Also, amifostine may reduce toxic effects of combination chemotherapy regimens that include paclitaxel...
  32. ncbi request reprint Neoadjuvant chemotherapy in head and neck cancer: should it be revisited?
    Pol M Specenier
    Department of Medical Oncology, University Hospital Antwerp, Wilrijkstraat 10, 2650 Edegem, Belgium
    Cancer Lett 256:166-77. 2007
    ....
  33. doi request reprint Difluorodeoxyuridine plasma concentrations after low-dose gemcitabine during chemoradiation in head and neck cancer patients
    P Specenier
    Medical Oncology, Antwerp University Hospital, Wilrijkstraat 10, 2650 Edegem, Belgium
    Cancer Chemother Pharmacol 68:185-91. 2011
    ....
  34. doi request reprint Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors
    E Calvo
    Hospital Universitario Vall d Hebron, Barcelona, Spain
    Cancer Chemother Pharmacol 69:1467-75. 2012
    ..Vinflunine is a new microtubule inhibitor of the vinca-alkaloid family. It is marketed in transitional cell carcinoma of urothelial tract as a 20 min infusion given every 3 weeks in Europe...
  35. ncbi request reprint Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study
    F Duffaud
    Department of Medical Oncology, La Timone University Hospital, Bld J Moulin, Marseilles 5, 13385, France
    Eur J Cancer 40:2748-52. 2004
    ..The most common grade 3-4 non-haematological toxicity was infection in 8.5% of patients. OSI-211 administered on d1 and d8, every 3 weeks, is well tolerated, but shows only minimal activity in locally advanced/metastatic SCCHN...
  36. ncbi request reprint The role of anthracyclines in epithelial ovarian cancer
    J B Vermorken
    Department of Medical Oncology, University Hospital Antwerp, Edegem, Belgium
    Ann Oncol 10:43-50. 1999
    ..It is important that the final conclusions of these studies are based on long-term survival data, not just on the assessment of median differences in survival...
  37. pmc Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature
    J Pelgrims
    Department of Medical Oncology, University Hospital Antwerp, Edegem, Belgium
    Br J Cancer 82:291-4. 2000
    ..Two developed milder encephalopathy; one had no CNS depression at all. We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy. Our findings suggest that it may also be used as a prophylactic agent...
  38. pmc Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)
    J B Vermorken
    Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium
    Ann Oncol 25:682-8. 2014
    ..Recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN) overexpresses αvβ5 integrin. Cilengitide selectively inhibits αvβ3 and αvβ5 integrins and is investigated as a treatment strategy...
  39. ncbi request reprint Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome
    T Van den Wyngaert
    Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium
    Ann Oncol 20:331-6. 2009
    ..Overall survival (OS) and outcome of cancer patients with bisphosphonate-associated osteonecrosis of the jaw (ONJ) using conservative treatment (chlorhexidine 0.12% rinse, intermittent antibiotics, and careful sequestrectomy) are unknown...
  40. ncbi request reprint Prevalence of human papillomavirus in elderly women with cervical cancer
    M F Baay
    Department of Medical Oncology, University of Antwerp, Wilrijk, Belgium
    Gynecol Obstet Invest 52:248-51. 2001
    ..Therefore, HPV detection can be equally well used in the management and follow-up of elderly cervical cancer patients...
  41. ncbi request reprint Is there still a role for neoadjuvant chemotherapy in head and neck cancer?
    L Licitra
    Medical Oncology Unit, Head and Neck Department, Istituto Nazionale Tumori, Milan, Italy
    Ann Oncol 15:7-11. 2004
    ..This article reviews current indications for neoadjuvant chemotherapy in advanced head and neck cancer. Implications for current and future research are discussed...
  42. ncbi request reprint The role of anthracyclines in second-line therapy of ovarian cancer
    J B Vermorken
    Department of Medical Oncology, University Hospital Antwerp, Edegem, Belgium
    Int J Gynecol Cancer 13:178-84. 2003
    ..It is concluded that both EPI and PLD can be recommended as a reasonable single-agent treatment option for relapsed patients, with a preference for PLD taking into account its more favorable toxicity profile...
  43. ncbi request reprint Microsatellite instability and HPV genotype in Polish women with cervical cancer
    M F D Baay
    Department of Medical Oncology, University of Antwerp UA UZA, Antwerp, Belgium
    Eur J Gynaecol Oncol 30:162-6. 2009
    ..The aim of this study was to investigate the incidence of microsatellite instability in cervical cancer and to see whether there is a relation between MSI, HPV and clinicopathological characteristics in the study population...
  44. ncbi request reprint Medical treatment in head and neck cancer
    J B Vermorken
    Department of Medical Oncology, University Hospital Antwerp, Edegem, Belgium
    Ann Oncol 16:ii258-64. 2005
  45. ncbi request reprint The role of hysterotomy in the management of gestational trophoblastic neoplasia
    W A A Tjalma
    Department of Gynecology, University Hospital Antwerpen UZA, Antwerpen, Belgium
    Int J Gynecol Cancer 16:882-3. 2006
    ..This report illustrates that it is mandatory to have a histologic diagnosis of chemoresistant gestational trophoblastic neoplasia before performing definitive surgery...
  46. doi request reprint Advances in the systemic treatment of head and neck cancers
    Pol Specenier
    Antwerp University Hospital, Department of Oncology, Wilrijkstraat 10, 2650 Edegem, Belgium
    Curr Opin Oncol 22:200-5. 2010
    ..To summarize the recent literature on the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck...
  47. doi request reprint Recurrent head and neck cancer: current treatment and future prospects
    Pol M Specenier
    Department of Medical Oncology, University Hospital Antwerp, Wilrijkstraat 10, 2650 Edegem, Belgium
    Expert Rev Anticancer Ther 8:375-91. 2008
    ..The next challenge will be to sort out which of them have a clinically meaningful activity and find out how to incorporate them into existing treatment regimens...
  48. ncbi request reprint Taxanes in the treatment of head and neck cancer
    Dirk Schrijvers
    Department of Medical Oncology, Middelheim Hospital, Antwerp, Belgium
    Curr Opin Oncol 17:218-24. 2005
    ....
  49. doi request reprint Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study
    Sevilay Altintas
    Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium
    Breast J 15:120-32. 2009
    ..Independent predictors for recurrence included size, margin width, pathologic class, and age, but none of the molecular markers were part of it. Overexpression of HER4 in the presence of HER3 was associated with a better DFS...
  50. ncbi request reprint The role of taxanes and targeted therapies in locally advanced head and neck cancer
    Pol Specenier
    Department of Medical Oncology, University Hospital Antwerp, Edegem, Belgium
    Curr Opin Oncol 19:195-201. 2007
    ..This review presents new data on the role of taxanes and targeted therapies in the management of squamous cell carcinoma of the head and neck...
  51. ncbi request reprint Current concepts for the management of head and neck cancer: chemotherapy
    Pol M Specenier
    Department of Medical Oncology, Antwerp University Hospital, Wilrijkstraat 10, 2650 Edegem, Belgium
    Oral Oncol 45:409-15. 2009
    ..However, a survival benefit was observed when cetuximab was combined with platinum-5-fluorouracil...
  52. doi request reprint Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study
    Pol Specenier
    Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium
    Anticancer Drugs 21:306-12. 2010
    ..It is associated with substantial haematological toxicity, but this is feasible provided prophylactic antibiotics are used...
  53. ncbi request reprint Docetaxel, ifosfamide and cisplatin (DIP) in squamous cell carcinoma of the head and neck
    Pol M Specenier
    Antwerp University Hospital, Department of Medical Oncology, Wilrijkstraat 10, 2650 Edegem, Belgium
    Anticancer Res 29:5137-42. 2009
    ....
  54. doi request reprint Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients
    Pol M Specenier
    Department of Medical Oncology, Antwerp University Hospital, Wilrijkstraat 10, 2650, Edegem, Belgium
    Cancer Chemother Pharmacol 64:233-41. 2009
    ..Secondary objectives were to assess the pharmacokinetics of pemetrexed when it is combined with cisplatin as well as to evaluate the safety profile and document antitumor activity associated with this combination...
  55. pmc Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial
    J B Vermorken
    Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium
    Ann Oncol 25:801-7. 2014
    ..This retrospective analysis of the EXTREME trial, comparing chemotherapy plus cetuximab with chemotherapy first line in R/M SCCHN, investigated efficacy and prognosis according to tumor p16 and HPV status...
  56. pmc EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer
    J Van den Brande
    Department of Medical Oncology, University Hospital Antwerp, Wilrijkstraat, Edegem, Belgium
    Br J Cancer 88:648-53. 2003
    ..The other toxicities were limited and manageable. S-1 is active in advanced colorectal cancer, but in order to establish a safer dose the drug should be subject to further investigations...
  57. ncbi request reprint The radiosensitising effect of gemcitabine and the influence of the rescue agent amifostine in vitro
    B Pauwels
    Laboratory of Cancer Research and Clinical Oncology, Department of Medical Oncology, University of Antwerp UIA UZA, Wilrijk, Belgium
    Eur J Cancer 39:838-46. 2003
    ....
  58. ncbi request reprint Phase I study of MEN-10755, a new anthracycline in patients with solid tumours: a report from the European Organization for Research and Treatment of Cancer, Early Clinical Studies Group
    D Schrijvers
    Department of Medical Oncology, University Hospital Antwerp, Edegem, Belgium
    Ann Oncol 13:385-91. 2002
    ..No responses were observed. MEN-107555 at a dose of 30 mg/m2/week in pretreated patients and 40 mg/m2/week in chemotherapy-naive patients for three consecutive weeks followed by 1 week rest is recommended for phase II testing...
  59. ncbi request reprint Methotrexate-associated liver toxicity in a patient with breast cancer: case report and literature review
    S van Outryve
    University Hospital of Antwerp, University of Antwerp, Department of Medical Oncology, Belgium
    Neth J Med 60:216-22. 2002
    ..In that sense, mitoxantrone appears to be a valuable alternative to methotrexate in cases of hepatotoxicity in patients with breast cancer. An overview of the literature regarding methotrexate hepatotoxicity is presented...
  60. ncbi request reprint Primary ovarian small cell carcinoma of the pulmonary type: a case report and review of the literature
    J Mebis
    Department of Medical Oncology, University Hospital Antwerp, Edegem, Belgium
    Eur J Gynaecol Oncol 25:239-41. 2004
    ..A review of the literature on small cell carcinoma of the ovary is given and the findings of our patient are brought into perspective in terms of both histopathogenesis and treatment outcome...
  61. ncbi request reprint Intergroup collaboration in ovarian cancer: the Gynecologic Cancer Intergroup (GCIG)
    J B Vermorken
    Department of Medical Oncology, University Hospital Antwerp, Edegem, Belgium
    Int J Gynecol Cancer 11:73-6. 2001
    ....
  62. pmc A non-randomized comparison of gemcitabine-based chemoradiation with or without induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck
    Pol M Specenier
    Department of Medical Oncology, Antwerp University Hospital Antwerp, Edegem, Belgium
    BMC Cancer 9:273. 2009
    ..Adding a taxane to PF in the IC regimen confers a better outcome. Sequential treatment (ST) of IC followed by CRT is therefore under active investigation in multiple phase III trials...
  63. ncbi request reprint Pneumonectomy for lung metastases: report of ten cases
    J M H Hendriks
    Department of Thoracic and Vascular Surgery, University of Antwerp, Edegem, Belgium
    Thorac Cardiovasc Surg 51:38-41. 2003
    ....
  64. ncbi request reprint Determination of compatibility and stability of drugs used in palliative care
    D Schrijvers
    Department of Medical Oncology, University Hospital Antwerp, Edegem, Belgium
    J Clin Pharm Ther 23:311-4. 1998
    ..Drugs for symptom control in the terminal phase of palliative patients may be used in pump systems...
  65. ncbi request reprint Acute hemiplegia caused by a retrograde cerebral venous air embolism after central venous catheter removal: an illustrative case
    S van Ierssel
    Department of Oncology, University Hospital of Antwerp, Antwerp, Belgium
    Acta Clin Belg 65:51-3. 2010
    ..This was accidentally performed with the patient in upright position. A CT scan of the brain demonstrated air in the sinus cavernosus bilaterally and at the posterior wall of the foramen magnum...
  66. ncbi request reprint Intraperitoneal chemotherapy in advanced ovarian cancer: recognition at last
    J B Vermorken
    Department of Medical Oncology, University Hospital Antwerp, Edegem, Belgium
    Ann Oncol 17:x241-6. 2006
  67. ncbi request reprint Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies
    Bea Pauwels
    Department of Medical Oncology, University of Antwerp UIA UZA, Universiteitsplein 1, 2610, Wilrijk, Belgium
    Cancer Chemother Pharmacol 51:221-6. 2003
    ..Since there is a growing interest in preclinical research on interactions between radiation and cytotoxic agents, this study focused on the development of an alternative to the very laborious clonogenic assay (CA)...
  68. ncbi request reprint The value of the Van Nuys Prognostic Index in ductal carcinoma in situ of the breast: a retrospective analysis
    Fernando Tjin Asjoe
    Department of Gynecology and Gynecological Oncology, University Hospital Antwerp, Wilrijkstraat, Edegem, Belgium
    Breast J 13:359-67. 2007
    ..However, this Index is not evidence-based, using a relatively small retrospective series of patients. The validity of the modified VNPI must be prospectively confirmed with large numbers of DCIS patients...
  69. ncbi request reprint Phase I studies with bendamustine: an update
    Dirk Schrijvers
    Department of Medical Oncology, University Hospital Antwerp, Edegem, Belgium
    Semin Oncol 29:15-8. 2002
    ..This article presents an overview of the recent phase I trials and a summary of ongoing clinical trials...
  70. ncbi request reprint Combination chemotherapy with gemcitabine with isolated lung perfusion for the treatment of pulmonary metastases
    Bart P Van Putte
    Departments of Thoracic and Vascular Surgery, University Hospital Antwerp, Wilrijkstraat 10, B 2650 Edegem, Belgium
    J Thorac Cardiovasc Surg 130:125-30. 2005
    ..Single-agent isolated lung perfusion does not result in complete remission. We studied the in vivo and in vitro efficacy of combinations of gemcitabine, cisplatin, and melphalan...
  71. ncbi request reprint Risk factors for cervical cancer development: what do women think?
    M F D Baay
    Department of Medical Oncology, University of Antwerp, Belgium
    Sex Health 1:145-9. 2004
    ..The aim of this study was to investigate what knowledge women have of the relation between HPV and cervical cancer...
  72. pmc Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients
    Vanessa Deschoolmeester
    Laboratory of Cancer Research and Clinical Oncology, Department of Medical Oncology, University of Antwerp UA UZA, Wilrijk, Belgium
    BMC Immunol 11:19. 2010
    ..Prognostic relevance was assessed by survival analysis...
  73. ncbi request reprint A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors
    Marika Rasschaert
    Department of Medical Oncology, University Hospital Antwerp, Belgium
    Anticancer Drugs 18:587-95. 2007
    ..Fatigue and cardiac toxicity were dose limiting. The plasma pharmacokinetics data of bendamustine and its metabolites were in accordance with previous reports. The recommended dose for future trials is 260 mg/m2 every 3 weeks...
  74. pmc Detection of HPV and the role of p16INK4A overexpression as a surrogate marker for the presence of functional HPV oncoprotein E7 in colorectal cancer
    Vanessa Deschoolmeester
    Laboratory of Cancer Research and Clinical Oncology, Department of Medical Oncology, University of Antwerp UA UZA, Wilrijk, Belgium
    BMC Cancer 10:117. 2010
    ..These findings were correlated with clinical and pathological prognostic factors of CRC...
  75. pmc A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy
    Vanessa Deschoolmeester
    Laboratory of Cancer Research and Clinical Oncology, Department of Medical Oncology, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium
    Oncologist 15:699-731. 2010
    ....
  76. ncbi request reprint Isolated lung perfusion with melphalan for resectable lung metastases: a phase I clinical trial
    Jeroen M H Hendriks
    Department of Thoracic and Vascular Surgery, University Hospital Antwerp, Edegem, Belgium
    Ann Thorac Surg 78:1919-26; discussion 1926-7. 2004
    ..A phase I trial of isolated lung perfusion with melphalan (MN) combined with pulmonary metastasectomy for resectable lung metastases was conducted to define the dose-limiting toxicity and maximum tolerated dose...
  77. pmc Comparative study of the radiosensitizing and cell cycle effects of vinflunine and vinorelbine, in vitro
    Cindy Simoens
    Laboratory of Cancer Research and Clinical Oncology, Department of Medical Oncology, University of Antwerp UA UZA, Wilrijk Antwerp, Belgium
    BMC Cancer 8:65. 2008
    ..In the present study, a direct comparison was made between vinflunine and vinorelbine regarding their radiosensitizing and cell cycle effects...
  78. ncbi request reprint Review: implications of in vitro research on the effect of radiotherapy and chemotherapy under hypoxic conditions
    An Wouters
    Laboratory of Cancer Research and Clinical Oncology, Department of Medical Oncology, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium
    Oncologist 12:690-712. 2007
    ..Next, we sketch an overview of preclinical and clinical research on radiotherapy, chemotherapy, and chemoradiation under hypoxic conditions...
  79. ncbi request reprint Bisphosphonates in oncology: rising stars or fallen heroes
    Tim Van den Wyngaert
    Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium
    Oncologist 14:181-91. 2009
    ..Finally, we address the need for a careful consideration of potential benefits of bisphosphonate therapy and the risk for osteonecrosis of the jaw, a recently recognized late-toxicity of their use...
  80. ncbi request reprint Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer
    Marshall Posner
    Head and Neck Oncology Program, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Semin Oncol 35:221-8. 2008
    ..This approach is promising and may have a survival advantage over chemoradiotherapy alone. Both TPF induction and sequential therapy are considered appropriate platforms upon which the new molecularly targeted agents can be tested...
  81. ncbi request reprint International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma
    J Baptist Trimbos
    Department of Gynecology, Leiden University Medical Center, The Netherlands
    J Natl Cancer Inst 95:105-12. 2003
    ..Adjuvant chemotherapy has been suggested as a possible strategy to improve survival in women with early-stage ovarian cancer; however, all randomized studies to date have been too small to answer this question reliably...
  82. ncbi request reprint Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial
    J Baptist Trimbos
    Leiden University Medical Center, Leiden, The Netherlands
    J Natl Cancer Inst 95:113-25. 2003
    ..We performed a prospective unblinded, randomized phase III trial to test the efficacy of adjuvant chemotherapy in patients with early-stage ovarian cancer, with emphasis on the extent of surgical staging...
  83. ncbi request reprint Targeted therapies in head and neck cancer: past, present and future
    Alexander D Rapidis
    Department of Maxillofacial Surgery, Greek Anticancer Institute Saint Savvas Hospital, 171 Alexandras Avenue, Athens 115 22, Greece
    Rev Recent Clin Trials 3:156-66. 2008
    ..These include the monoclonal antibody (MAb) cetuximab and the tyrosine kinase inhibitors, erlotinib and gefitinib. Clinical data for the vascular endothelial growth factor (VEGF) inhibitor, bevacizumab, are also presented...
  84. ncbi request reprint Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group
    Markus Joerger
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Clin Cancer Res 13:6410-8. 2007
    ..05 to 0.2 micromol/L (t(C > 0.05-0.2)) predicts neutropenia. The objective of this study was to build a population pharmacokinetic-pharmacodynamic model of paclitaxel/carboplatin in ovarian cancer patients...
  85. ncbi request reprint Adjuvant therapy in patients with resected poor-risk head and neck cancer
    Jacques Bernier
    Clinique de Genolier, Genolier, Switzerland
    J Clin Oncol 24:2629-35. 2006
    ....
  86. ncbi request reprint The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent
    Jan P A Baak
    Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands, and Department of Pathology, Stavanger University Hospital, P O Box 8100, 4068 Stavanger, Norway
    Eur J Cancer 43:527-35. 2007
    ..006) for patients aged 55-70 years, while over 70 years, MAI was not significant (P=.11). The prognostic value of proliferation was age-dependent. Prognostic breast cancer studies must clearly indicate the age group being studied...
  87. ncbi request reprint Ovarian cancer in the elderly
    Sandro Pignata
    Division of Medical Oncology B, National Cancer Institute of Naples, Via M Semmola, I 80131 Naples, Italy
    Crit Rev Oncol Hematol 49:77-86. 2004
    ....
  88. ncbi request reprint Taxanes in head and neck cancer
    Dirk Schrijvers
    Department Medical Oncology, Ziekenhuisnetwerk Antwerpen Campus Middelheim, Lindendreef 1, Antwerp, Belgium
    Future Oncol 1:829-39. 2005
    ..This article reviews of both docetaxel and paclitaxel data in this patient population. Taxanes do not yet have a a license for use in the standard treatment of patients with head and neck cancer in Europe...
  89. ncbi request reprint Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years
    Jan P A Baak
    Department of Pathology and Epidemiology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    J Clin Oncol 23:5993-6001. 2005
    ..To validate the independent strong prognostic value of mitotic activity index (MAI) in lymph node (LN) -negative invasive breast cancer patients younger than 55 years in a nationwide multicenter prospective study...
  90. ncbi request reprint Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study
    Charlotte Van Kesteren
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Amsterdam, The Netherlands
    Anticancer Drugs 13:381-93. 2002
    ..Administration of 1650 microg/m(2) ET-743 over 3 h seemed clinically feasible; pharmacokinetics were linear with this schedule. Hepatic and hematological toxicities correlated with exposure to ET-743...
  91. ncbi request reprint Combined modality therapy of gemcitabine and radiation
    Bea Pauwels
    Laboratory of Cancer Research and Clinical Oncology, University of Antwerp, Campus Drie Eiken, Universiteitsplein 1, 2610 Wilrijk, Belgium
    Oncologist 10:34-51. 2005
    ..In the current review, the preclinical data that support the use of gemcitabine as a radiosensitizing agent and the clinical trials that have been conducted to date are summarized...
  92. ncbi request reprint Success predictors of adjuvant chemotherapy in node-negative breast cancer patients under 55 years
    Emiel A M Janssen
    Department of Pathology, Stavanger University Hospital, Stavanger, Norway
    Cell Oncol 28:295-303. 2006
    ..The majority of (LN-) patients receive ASCT when the St. Gallen criteria or its modifications are used, as accurate identifiers which patients benefit from ASCT are lacking. This may imply over-treatment in many patients...